Our Management Team
PRESIDENT & CHIEF EXECUTIVE OFFICER
Christopher A. Thatcher
Christopher A. Thatcher was named Noxilizer’s President and CEO in May 2024. He is a seasoned business leader with over 25 years of experience driving and turning around revenue and earnings growth in the global medical device, equipment, pharmaceutical, and healthcare products sectors. His extensive leadership experience includes roles as President of Integra LifeSciences’ Neurosurgery Division, Country Manager of Canada at Bausch and Lomb and Vice President of Global Strategy and Commercial Development at Bausch & Lomb. Additionally, as President and CEO he successfully raised significant capital and took Neuronetics public in an IPO in 2018. Christopher also serves on the Board of Directors for Noxilizer, Micro Interventional Devices and Strategic Advisor for Sinaptica Therapeutics. Mr. Thatcher holds a B.A. from Lafayette College.
SENIOR VICE PRESIDENT, BUSINESS DEVELOPMENT & MARKETING
Maura O. Kahn
Has 20 years of health care experience. Most recently, Maura was Senior Director of Marketing at MedImmune, responsible for developing and executing the marketing strategy and plan for Synagis. This franchise represents over 80% of total revenue for the company. Maura spent nine years at Eli Lilly in US Diabetes Marketing, Sales Management, Business Development and Global New Product Planning. She was a member of the US Humalog launch team, led the US launch of the Humulin/Humalog Pen and initiated the first ever direct-to-consumer campaign at Lilly. She was a member of the deal teams in Lilly’s successful negotiations with Takeda for Actos and Amylin for Byetta. She began her career at Targeted Communications and The RTC Group. Her clients included political candidates, trade associations and Fortune 500 companies. Ms. Kahn received her B.A. from Saint Mary’s College in Indiana and her MBA from the Kelley School of Business at Indiana University.
SENIOR VICE PRESIDENT, RESEARCH AND DEVELOPMENT
David Opie, Ph.D.
Has extensive medical device experience with both start-up companies and industry leaders, including Johnson & Johnson and Cook Medical. He has developed a thorough knowledge of Good Laboratory Practices, Good Manufacturing Practices, and design control procedures. At Noxilizer he leads the technology development and sterilization science initiatives. In addition to membership in several industry organizations, he participates in AAMI standards committees related to sterilization and decontamination. Dr. Opie holds a Ph.D. and an M.S. in physics from the College of William and Mary in Virginia, and a B.A. in Physics from the University of Delaware.